Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jul 2019 · 1 min read
In brief
In brief
Phase II trial evaluating everolimus plus bevacizumab in 25 patients with refractory MPNST (17 NF1-related, 8 sporadic) achieved only 12% clinical benefit rate, falling short of the 25% target. The mTOR/angiogenesis inhibitor combination is not considered active for this indication despite biological rationale.
Written by the GCMD Library team from the article.
Statements in this article
There are no known effective medical treatments for refractory MPNST.
Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR signaling and angiogenesis, which contributes to disease progression.
Everolimus was administered at 10 mg PO once daily in combination with bevacizumab 10 mg/kg IV every 2 weeks.
Clinical benefit rate was defined as complete response, partial response, or stable disease for at least 4 months.
Patients 18 years or older with chemotherapy refractory sporadic or NF1 MPNST were eligible for enrollment.
Tumor response was assessed after every 2 cycles using the WHO criteria.
The study used a two-stage design targeting a 25% clinical benefit rate, requiring at least 1 of 15 patients in stage 1 to respond for expansion and at least 4 of 25 patients to have clinical benefit for the combination to be considered active.
Twenty-five patients enrolled, including 17 with NF1 and 8 with sporadic MPNST.
One of 15 patients in stage 1 had clinical benefit.
Two of 10 additional patients enrolled in stage 2 had clinical benefit.
The median number of completed cycles was 3, with a range of 1 to 16 cycles.
The clinical benefit rate was 12% (3 of 25 patients).
The combination of everolimus and bevacizumab did not reach the study's target response rate and is not considered active in refractory MPNST.